Automatic gross tumor volume segmentation with failure detection for safe implementation in locally advanced cervical cancer.

Adaptive radiotherapy Automatic segmentation Deep learning Failure detection Locally advanced cervical cancer Quality assurance

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 03 10 2023
revised: 08 04 2024
accepted: 08 04 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: epublish

Résumé

Automatic segmentation methods have greatly changed the RadioTherapy (RT) workflow, but still need to be extended to target volumes. In this paper, Deep Learning (DL) models were compared for Gross Tumor Volume (GTV) segmentation in locally advanced cervical cancer, and a novel investigation into failure detection was introduced by utilizing radiomic features. We trained eight DL models (UNet, VNet, SegResNet, SegResNetVAE) for 2D and 3D segmentation. Ensembling individually trained models during cross-validation generated the final segmentation. To detect failures, binary classifiers were trained using radiomic features extracted from segmented GTVs as inputs, aiming to classify contours based on whether their Dice Similarity Coefficient Segmentation by 2D-SegResNet achieved the best DSC, Surface DSC ( Our study revealed that segmentation accuracy varies slightly among different DL methods, with 2D networks outperforming 3D networks in 2D MRI sequences. Doctors found the time-saving aspect advantageous. The proposed failure detection could guide doctors in sensitive cases.

Sections du résumé

Background and Purpose UNASSIGNED
Automatic segmentation methods have greatly changed the RadioTherapy (RT) workflow, but still need to be extended to target volumes. In this paper, Deep Learning (DL) models were compared for Gross Tumor Volume (GTV) segmentation in locally advanced cervical cancer, and a novel investigation into failure detection was introduced by utilizing radiomic features.
Methods and materials UNASSIGNED
We trained eight DL models (UNet, VNet, SegResNet, SegResNetVAE) for 2D and 3D segmentation. Ensembling individually trained models during cross-validation generated the final segmentation. To detect failures, binary classifiers were trained using radiomic features extracted from segmented GTVs as inputs, aiming to classify contours based on whether their Dice Similarity Coefficient
Results UNASSIGNED
Segmentation by 2D-SegResNet achieved the best DSC, Surface DSC (
Conclusions UNASSIGNED
Our study revealed that segmentation accuracy varies slightly among different DL methods, with 2D networks outperforming 3D networks in 2D MRI sequences. Doctors found the time-saving aspect advantageous. The proposed failure detection could guide doctors in sensitive cases.

Identifiants

pubmed: 38912007
doi: 10.1016/j.phro.2024.100578
pii: S2405-6316(24)00048-4
pmc: PMC11192799
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100578

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Gustave Roussy has received financial support from Elekta company for the completion of the study.

Auteurs

Rahimeh Rouhi (R)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Stéphane Niyoteka (S)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Alexandre Carré (A)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Samir Achkar (S)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Pierre-Antoine Laurent (PA)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Mouhamadou Bachir Ba (MB)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Radiotherapy Department of the University Hospital Center of Dalal Jamm, Guédiawaye, Senegal.

Cristina Veres (C)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Théophraste Henry (T)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Medical Imaging, Gustave Roussy Cancer Campus, Villejuif, France.

Maria Vakalopoulou (M)

Laboratoire Mathématiques et Informatique pour la Complexité et les Systèmes, CentraleSupélec, Université Paris-Saclay, Gif-sur-Yvette, France.

Roger Sun (R)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Sophie Espenel (S)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Linda Mrissa (L)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Adrien Laville (A)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.

Cyrus Chargari (C)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Eric Deutsch (E)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Charlotte Robert (C)

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, 94800 Villejuif, France.
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Classifications MeSH